OBJECTIVE: The aim of the study was to investigate differences in 5-HT(2A) receptor binding between healthy volunteers and patients with major depressive disorder (MDD), either never treated before with antidepressants (drug-naive: DN) or responding to paroxetine treatment (drug-treated: DT). METHODS: Nineteen DN patients with MDD and 15 euthymic DT (paroxetine 4 weeks) patients were compared with a group of 20 healthy controls (C) with positron emission tomography (PET) using [(18)F]fluoroethylspiperone ([(18)F]FESP), a 5-HT(2A) and D(2) receptor antagonist. A "binding index" (BI) of [(18)F]FESP to cortical and basal ganglia regions was calculated as the ratio of the activity in these regions to that of cerebellum. Differences in BI between groups, i.e. C versus DN or DT, were assessed by ANOVA, with or without age as covariate (ANCOVA). RESULTS: A significant reduction in BI ( P=0.003 ANOVA, P=0.001 ANCOVA) was found in DN patients in the frontal, occipital, temporal and cingulate cortices, but not in the striatum. No significant differences emerged between C and DT patients. CONCLUSIONS: The reduction of [(18)F]FESP BI in cortical areas of DN depressed, but not of euthymic DT patients suggests an association between the occurrence of depressive symptoms and impairment of cortical 5-HT(2A) receptors. [(18)F]FESP cortical BI may represent a state marker of depression.
OBJECTIVE: The aim of the study was to investigate differences in 5-HT(2A) receptor binding between healthy volunteers and patients with major depressive disorder (MDD), either never treated before with antidepressants (drug-naive: DN) or responding to paroxetine treatment (drug-treated: DT). METHODS: Nineteen DNpatients with MDD and 15 euthymic DT (paroxetine 4 weeks) patients were compared with a group of 20 healthy controls (C) with positron emission tomography (PET) using [(18)F]fluoroethylspiperone ([(18)F]FESP), a 5-HT(2A) and D(2) receptor antagonist. A "binding index" (BI) of [(18)F]FESP to cortical and basal ganglia regions was calculated as the ratio of the activity in these regions to that of cerebellum. Differences in BI between groups, i.e. C versus DN or DT, were assessed by ANOVA, with or without age as covariate (ANCOVA). RESULTS: A significant reduction in BI ( P=0.003 ANOVA, P=0.001 ANCOVA) was found in DNpatients in the frontal, occipital, temporal and cingulate cortices, but not in the striatum. No significant differences emerged between C and DTpatients. CONCLUSIONS: The reduction of [(18)F]FESP BI in cortical areas of DNdepressed, but not of euthymic DTpatients suggests an association between the occurrence of depressive symptoms and impairment of cortical 5-HT(2A) receptors. [(18)F]FESP cortical BI may represent a state marker of depression.
Authors: D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass Journal: Science Date: 1984-12-21 Impact factor: 47.728
Authors: D Attar-Lévy; J L Martinot; J Blin; M H Dao-Castellana; C Crouzel; B Mazoyer; M F Poirier; M C Bourdel; N Aymard; A Syrota; A Féline Journal: Biol Psychiatry Date: 1999-01-15 Impact factor: 13.382
Authors: Leo Sher; Matthew S Milak; Ramin V Parsey; Juan J Carballo; Thomas B Cooper; Kevin M Malone; Maria A Oquendo; J John Mann Journal: Eur Neuropsychopharmacol Date: 2007-05-02 Impact factor: 4.600
Authors: K Peremans; K Audenaert; Y Hoybergs; A Otte; I Goethals; I Gielen; P Blankaert; M Vervaet; C van Heeringen; R Dierckx Journal: Eur J Nucl Med Mol Imaging Date: 2005-06 Impact factor: 9.236
Authors: Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye Journal: Neuropsychopharmacology Date: 2004-06 Impact factor: 7.853
Authors: Sofia I I Kring; Thomas Werge; Claus Holst; Søren Toubro; Arne Astrup; Torben Hansen; Oluf Pedersen; Thorkild I A Sørensen Journal: PLoS One Date: 2009-08-19 Impact factor: 3.240